Skip to main content

Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer

  • Protocol
  • First Online:
Natural Killer Cells

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1441))

Abstract

Natural killer (NK) cells are an attractive cell population for immunotherapy. Adoptive transfer of NK cells has been tested in multiple clinical trials including acute myeloid leukemia (AML) and ovarian cancer, although limitations do exist especially for treatment of solid tumors. In order to overcome these limitations, mouse xenograft models are needed for evaluation of various NK cell populations, as well as routes of NK cell administration. Here, we describe the methods used for the establishment of an intraperitoneal (ip) ovarian cancer mouse xenograft model with ip delivery of NK cells. This model has been successfully employed with multiple ovarian cell lines and could be applied to other tumor models where the tumor’s primary location is in the peritoneal cavity. It is also compatible with multiple routes of NK cell administration. Bioluminescent imaging for monitoring tumor formation and response provides for easy visualization of NK cell tumor inhibition. This xenograft model is superior to other models because the tumor is implanted into the same physiological space where ovarian cancer is found, which allows for improved mimicking of actual disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vivier E, Raulet DH, Moretta A et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44–49

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057

    Article  CAS  PubMed  Google Scholar 

  3. Geller MA, Cooley S, Judson PL et al (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98–107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cheng M, Chen Y, Xiao W, Sun R, Tian Z (2013) NK cell—based immunotherapy for malignant diseases. Cell Mol Immunol 10:230–252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tonn T, Schwabe D, Klingemann HG et al (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15:1563–1570

    Article  CAS  PubMed  Google Scholar 

  6. Koepsell SA, Miller JS, McKenna DH (2013) Natural killer cells: a review of manufacturing and clinical utility. Transfusion 53:404–410

    Article  CAS  PubMed  Google Scholar 

  7. Fujisaki H, Kakuda H, Shimasaki N et al (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69:4010–4017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Denman CJ, Senyukov VV, Somanchi SS et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7, e30264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Knorr DA, Ni Z, Hermanson D et al (2013) Clinical—scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med 2:274–283

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ni Z, Knorr DA, Kaufman DS (2013) Hematopoietic and nature killer cell development from human pluripotent stem cells. Methods Mol Biol 1029:33–41

    Article  CAS  PubMed  Google Scholar 

  11. Woll PS, Martin CH, Miller JS, Kaufman DS (2005) Human embryonic stem cell—derived NK cells acquire functional receptors and cytolytic activity. J Immunol 175:5095–5103

    Article  CAS  PubMed  Google Scholar 

  12. Woll PS, Grzywacz B, Tian X et al (2009) Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113:6094–6101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Geller MA, Knorr DA, Hermanson DA et al (2013) Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy 15:1297–1306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shultz LD, Lyons BL, Burzenski LM et al (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:6477–6489

    Article  CAS  PubMed  Google Scholar 

  15. Miller JS, Rooney CM, Curtsinger J et al (2014) Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant 20:1252–1257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dan S. Kaufman .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Hermanson, D.L., Bendzick, L., Kaufman, D.S. (2016). Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer. In: Somanchi, S. (eds) Natural Killer Cells. Methods in Molecular Biology, vol 1441. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3684-7_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3684-7_23

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3682-3

  • Online ISBN: 978-1-4939-3684-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics